VOR Stock Risk & Deep Value Analysis
Vor Biopharma Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About VOR Stock
We analyzed Vor Biopharma Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VOR through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VOR Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
Low-Medium
Market
Medium
Competitive
Medium
Execution
Medium
Regulatory
High
Upcoming Risk Events
- đź“…
Negative or inconclusive clinical trial results for VBP101/VCAR33
- đź“…
Slower than expected patient enrollment in ongoing trials
- đź“…
Adverse regulatory feedback or delays in clinical development path
- đź“…
Need for additional significant financing before projected runway, leading to substantial dilution
Unlock VOR Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Vor Biopharma Inc (VOR) Do?
Market Cap
$207.13M
Sector
Healthcare
Industry
Biotechnology
Employees
154
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit Vor Biopharma Inc WebsiteInvestment Thesis
Vor Biopharma is a high-conviction, high-risk play on a potentially transformative cell therapy platform. Its 'Mine-Resistant™' technology aims to redefine treatment for AML by protecting healthy cells, allowing for more aggressive and effective targeted therapies. The recent $110 million private placement, extending its cash runway into H2 2027, significantly de-risks the financial outlook and provides ample time for critical clinical data readouts for VBP101 and its combination with VCAR33. Positive clinical outcomes could establish a new standard of care, leading to substantial market penetration and a significant re-rating towards a 10x return within the next 3-5 years.
Is VOR Stock Undervalued?
Unlock the full AI analysis for VOR
Get the complete DVR score, risk analysis, and more
VOR Price Targets & Strategy
12-Month Target
$32.00
Bull Case
$75.00
Bear Case
$4.00
Entry Strategy
Dollar-cost average between $10-$15, especially on any dips not related to clinical setbacks. Accumulate before major data readouts.
Exit Strategy
Take 30% profit at $30, another 30% at $50. Stop loss at $8.00 if thesis breaks due to significant negative clinical news or unexpected dilution.
Portfolio Allocation
5-10% for aggressive risk tolerance. 2-4% for moderate risk tolerance.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Does VOR Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability hinges significantly on successful clinical validation of its 'Mine-Resistant™' platform, followed by robust patent protection for its gene-edited hematopoietic stem cells (HSPCs) and the combination therapy approach. If VBP101/VCAR33 becomes a standard of care, the regulatory approvals and established clinical efficacy will create high barriers to entry.
Moat Erosion Risks
- •Clinical trial failure, rendering the underlying technology unproven.
- •Emergence of superior or alternative technologies that negate the need for VOR's approach.
- •Intellectual property challenges or difficulty in maintaining exclusivity for its platform.
VOR Competitive Moat Analysis
Sign up to see competitive advantages
VOR Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral
Institutional Sentiment
Positive
Insider Activity (Form 4)
No significant insider buying or selling since the private placement. Activity is generally stable.
Options Flow
Relatively low options volume, with some speculative call buying indicating bullish interest around potential clinical catalysts. No significant bearish activity.
Earnings Intelligence
Next Earnings
2026-05-09 (Estimated)
Surprise Probability
Medium
Historical Earnings Pattern
Stock price reaction is highly volatile and primarily driven by clinical news and financial runway updates rather than traditional earnings beats/misses, as the company is pre-revenue.
Key Metrics to Watch
Competitive Position
Top Competitor
ALLO
Market Share Trend
Not applicable yet as the company is pre-commercial and seeking to establish a novel treatment paradigm.
Valuation vs Peers
Trading at a discount to many late-stage cell therapy peers, reflecting its earlier clinical stage and unique platform. Valuation is primarily driven by pipeline potential rather than current financial metrics.
Competitive Advantages
- •Proprietary 'Mine-Resistant™' technology platform, protecting healthy cells from targeted therapies.
- •Potential to combine with existing and pipeline CD33-targeted therapies (e.g., CAR-T), creating a broader applicability.
- •Addresses a critical unmet need in AML, potentially enabling curative outcomes for more patients.
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive VOR Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (estimated early May 2026)
- •Updates on VBP101 and VCAR33 clinical trial enrollment progress
- •Potential initial safety data from VBP101/VCAR33 combination therapy
Medium-Term (6-18 months)
- •Interim clinical data readouts (safety, engraftment, preliminary efficacy signals) for VBP101/VCAR33 combination therapy (mid-late 2026)
- •Potential expansion of clinical trials to additional cohorts or indications
- •Pre-clinical data updates on pipeline assets beyond VOR301
Long-Term (18+ months)
- •Initiation of pivotal clinical trials (Phase 2/3) based on positive Phase 1/2 data
- •Potential strategic partnerships or licensing agreements driven by strong data
- •Establishment of VOR's 'Mine-Resistant™' platform as a new standard of care in targeted cell therapies for blood cancers
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for VOR?
- âś“
Positive safety and efficacy data from VBP101/VCAR33 clinical trials
- âś“
Acceleration in patient enrollment or expansion into new clinical indications
- âś“
Announcements of new strategic partnerships or licensing agreements for platform validation
- âś“
Unexpected cash burn increase or need for further dilutive financing beyond current runway
Bull Case Analysis
See what could go right with Premium
Competing with VOR
See how Vor Biopharma Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vor Biopharma Inc VOR | $207.1M | 8.8 | — | — | — | — | |
Sarepta Therapeutics Inc SRPT | $2.3B | 4.1 | -2.6 | $2.4B | -38.3% | -32.7% | Compare → |
đź“Š Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Vor Biopharma Inc (VOR)?
As of March 20, 2026, Vor Biopharma Inc has a DVR Score of 8.8 out of 10, placing it in the "Hidden Gem" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vor Biopharma Inc?
Vor Biopharma Inc's market capitalization is approximately $207.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Vor Biopharma Inc use?
VOR is the ticker symbol for Vor Biopharma Inc. The company trades on the NMS.
What is the risk level for VOR stock?
Our analysis rates Vor Biopharma Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the VOR DVR analysis updated?
Our AI-powered analysis of Vor Biopharma Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 20, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VOR (Vor Biopharma Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.